Similar articles for PMID: 15313890

Year	Number of Results
2001	1
2002	5
2003	20
2004	29
2005	16
2006	17
2007	17
2008	12
2009	14
2010	10
2011	11
2012	9
2013	18
2014	12
2015	9
2016	7
2017	10
2018	9
2019	3
2020	2
2021	3
2022	2
2023	4
2024	0

1

SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.

Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL. Tsavachidou D, et al. Cancer Res. 2004 Aug 15;64(16):5556-9. doi: 10.1158/0008-5472.CAN-04-1669. Cancer Res. 2004. PMID: 15313890

2

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Satyamoorthy K, et al. Cancer Res. 2003 Feb 15;63(4):756-9. Cancer Res. 2003. PMID: 12591721

3

Suppression of BRAF(V599E) in human melanoma abrogates transformation.

Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Hingorani SR, et al. Cancer Res. 2003 Sep 1;63(17):5198-202. Cancer Res. 2003. PMID: 14500344

4

Microarray expression profiling in melanoma reveals a BRAF mutation signature.

Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringnér M, Hayward NK. Pavey S, et al. Oncogene. 2004 May 20;23(23):4060-7. doi: 10.1038/sj.onc.1207563. Oncogene. 2004. PMID: 15048078

5

Spry2 expression correlates with BRAF mutation in thyroid cancer.

Xu L, Zhou JL, Cohen M, Bar-Sagi D, Patel KN. Xu L, et al. Surgery. 2010 Dec;148(6):1282-7; discussion 1287. doi: 10.1016/j.surg.2010.09.028. Surgery. 2010. PMID: 21134562

6

Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.

Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, Benson EM, Kurnick JT. Kono M, et al. Mol Cancer Res. 2006 Oct;4(10):779-92. doi: 10.1158/1541-7786.MCR-06-0077. Mol Cancer Res. 2006. PMID: 17050671

7

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Kumar SM, et al. Cancer Res. 2007 Apr 1;67(7):3177-84. doi: 10.1158/0008-5472.CAN-06-3312. Cancer Res. 2007. PMID: 17409425

8

Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines.

Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Schuierer MM, et al. Cancer Res. 2004 Aug 1;64(15):5186-92. doi: 10.1158/0008-5472.CAN-03-3861. Cancer Res. 2004. PMID: 15289323

9

Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W. Sutterlüty H, et al. Mol Cancer Res. 2007 May;5(5):509-20. doi: 10.1158/1541-7786.MCR-06-0273. Mol Cancer Res. 2007. PMID: 17510316

10

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Sharma A, et al. Cancer Res. 2005 Mar 15;65(6):2412-21. doi: 10.1158/0008-5472.CAN-04-2423. Cancer Res. 2005. PMID: 15781657

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

224 results

Results by year